This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



NEXEL is a South Korean biotechnology company specializing in stem cell technology with two main pipelines: developing protein-based therapeutic candidates and human iPSC-derived cells. We aim to create innovative new therapies to help patients and provide tools for researchers to boost their projects. 

NEXEL is a world leader in iPSC (induced Pluripotent Stem Cell) technology as the first Korean company to license iPSC technology setting a new paradigm in the in vitro toxicity field through successful commercialization of iPSC-derived cells which mimic actual human functionality. We have successfully developed several off-the-shelf products such as cardiomyocytes, hepatocytes, and neurons. hiPSC-derived cells are proving to be an excellent in vitro model to potentially revolutionize preclinical drug toxicity testing, as evidenced by upcoming ICH guideline changes (S7B) with CiPA. NEXEL also provides a novel NeXST-Cardiac Safety Service, using our iPSC-cardiomyocytes (Cardiosight®-S), making costs and experimental designs flexible.

NEXEL has also expanded its offerings to custom cell line development (iPSCs) and customized differentiations/process development on a contract basis. Accelerate your cell therapy program discovery with our tailored services.

Furthermore, we are investing our expertise in discovering and developing new drug candidates based on proteins and peptides derived from stem cell technology. Our lead product candidate, NP-011, was designed by modifying a specific multifunctional protein found in embryonic stem cell secretome. It has shown potent anti-inflammatory and anti-fibrotic activity in multiple animal models and is under development for the treatment of NASH-related fibrosis and inflammatory bowel disease (IBD). We are presently conducting Phase I trials of NP-011 in Australia. NEXEL’s other promising drug candidate, NPT-0025, is a peptide, selective inhibitor of specific integrins being developed for the treatment of idiopathic pulmonary fibrosis (IPF). 

Our team comprises talented individuals who share a passion for innovation and high scientific standards. In addition, our valuable collaborators assist us within the academic and clinical communities.